In the realm of intellectual property, few disputes impact science, business, and medicine as profoundly as the years-long battle over patents for CRISPR technology (“genetic scissors”). In March 2026, this conflict took a new turn: Nobel laureates Jennifer Doudna and Emmanuelle Charpentier once again lost a pivotal ruling in the United States.
The Heart of the Dispute: Who “Invented” CRISPR for Human Cells?
CRISPR is a revolutionary gene-editing technology often referred to as “biological scissors.” It enables:
-
Precise DNA modification
-
Potential cures for genetic diseases
-
The creation of novel biotechnologies
Despite Doudna and Charpentier receiving the 2020 Nobel Prize for the discovery of CRISPR, the patent issue has proven far more complex. The primary conflict arose between:
-
Their consortium (University of California + partners)
-
The Broad Institute (a joint project of Harvard and MIT)
The Key Question: Who was the first to prove that CRISPR works in eukaryotic cells (i.e., human, animal, and plant cells)?
The 2026 Ruling: A Second Defeat
In March 2026, the Patent Trial and Appeal Board (PTAB) once again ruled in favor of the Broad Institute. The board concluded that:
-
The Broad Institute was the first to reduce the technology to practice in complex cells.
-
The Doudna and Charpentier team failed to establish priority of invention.
This marks the second such decision following a 2022 ruling that was reviewed but ultimately left unchanged.
Why This Matters
While it may seem like a mere legal dispute, the stakes are colossal:
-
Foundation of Future Medicine: CRISPR is the backbone of gene therapy, cancer treatment, and future biotechnologies.
-
Market Control: Patents determine who receives billions in licensing royalties and who controls the market. This case is frequently called the “biotech patent war of the century.”
Why a Nobel Prize ≠ a Patent
This case highlights a crucial distinction:
-
The Nobel Prize recognizes a scientific discovery.
-
A Patent protects a specific technical application.
The court essentially ruled that an idea is not an invention until it is implemented. The Broad Institute successfully demonstrated that they were the first to “bring the technology to a working state” in human cells.
Is the Battle Over?
No. Despite this setback, the Doudna and Charpentier team holds more than 60 other CRISPR-related patents. The war is far from over.
Conclusion
The CRISPR story demonstrates that in the modern world:
-
A brilliant idea is only the beginning.
-
True value emerges at the stages of implementation and patenting.
The defeat of the Nobel laureates is not just legal news; it is a signal to the entire innovation economy: in the technology race, the winner is not just the one who discovers, but the one who successfully secures the rights.
Founder of Research & Patent group Intectica, author of patent algorithms for solving problems in the pharmaceutical industry, patent attorney certified in all intellectual property objects (Patents, Design, TM), with education in chemistry and law, chief expert of the patent institution of Ukraine UKRPATENT (1997-2004). Member of international organizations, including ECTA, PTMG, UAM, lecturer and blogger.
